Results 191 to 200 of about 9,287,329 (300)

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Colonia Uceda Renteria, Annapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

Role of Ultrasonography in the Diagnosis of Splenic Diseases. [PDF]

Diagnostics (Basel)
Naganuma H, Ishida H.
europepmc   +1 more source

ALBI‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

Alimentary Pharmacology &Therapeutics, EarlyView.
ALBI‐6, a novel score combining albumin–bilirubin grade and interleukin‐6, showed improved prognostic discrimination compared with established scores in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, supporting its potential use for risk stratification in this setting.
Paula Bark, Lucas Wiesmann, Simon Johannes Gairing, Kateryna Shmanko, Lukas Müller, Maximilian Moos, Fabian Stöhr, Dirk Graafen, Tilman Emrich, Felix Hahn, Daniel Pinto dos Santos, Bernhard Scheiner, Victoria Berit Berger, Matthias Pinter, Valentina Zarka, Florian P. Reiter, Andreas Geier, Najib Ben Khaled, Alexander Philipp, Christoph Springfeld, Aurelie Tomczak, Michael T. Dill, Constantin Scholz, Jens Mittler, Hauke Lang, Beate Katharina Straub, Roman Kloeckner, Tobias Bäuerle, Christian Markus Lange, Arndt Weinmann, Peter Robert Galle, Friedrich Foerster   +31 more
wiley   +1 more source

Possibilities for Cytoprotective Liver Therapy, Stable Gastric Pentadecapeptide BPC 157, and Standard Agents-A Narrative Review. [PDF]

Pharmaceuticals (Basel)
Sever M, Zenko Sever A, Klicek R, Kralj L, Dolic MP, Luetic K, Bekic D, Belosic Halle Z, Sucic M, Sikiric S, Beketic Oreskovic L, Bacic A, Strbe S, Staresinic E, Seiwerth S, Sikiric P, Boban Blagaic A, Dobric I, Staresinic M, Skrtic A.   +19 more
europepmc   +1 more source

Review Article: Fibrosis‐4 Index in Steatotic Liver Disease—Past, Present and Future

Alimentary Pharmacology &Therapeutics, EarlyView.
FIB‐4 remains an inexpensive, scalable first‐line triage tool for excluding advanced fibrosis and identifying patients who need second‐line assessment, but it should not be used as a stand‐alone diagnostic or treatment‐selection test. Sequential testing and longitudinal FIB‐4 trajectories may improve risk stratification and prognosis.
Kriti Soni, Vinay Jahagirdar, Omar Albhaisi, Richard K. Sterling, Juan Pablo Arab, Hanna Blaney, Luis Antonio Díaz   +6 more
wiley   +1 more source

Arterial Hypertension is Associated with a Lower Portal Hypertensive Burden in Compensated Cirrhosis: A Retrospective Cohort Study. [PDF]

Clin Exp Gastroenterol
Buono R, La Franca M, Girardi P, Di Pascoli M.   +3 more
europepmc   +1 more source

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir, Anjana Kumar, Alistair McArdle, Emily Holden, Leo Alexandre, Simon Rushbrook, Kate D. Lynch   +6 more
wiley   +1 more source

Silent Congestion: Chronic Budd-Chiari Syndrome Unmasked by Acute Decompensation. [PDF]

Cureus
McClusky J, Gill J, Mbachi C.
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source